Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

References

• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;669–76.
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 1999;13(1), 9–22.
   PubMed Web of Science ®Google Scholar
• Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J, Su C, Tan L, Li X. Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina. 2016;36(5), 938–43.
   PubMed Web of Science ®Google Scholar
• Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95(2), 548–53.
   PubMed Web of Science ®Google Scholar
• Lin T, Dans K, Meshi A, Muftuoglu IK, Amador-Patarroyo MJ, Chen KC, Cheng L, Freeman WR. Age-related macular degeneration-associated peripapillary choroidal neovascularization in the era of anti-vascular endothelial growth factor therapy. Retina. 2019;39(10), 1936–44.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang Y, Xie J, Li D, Hu Q, Li X, Zheng W, He R. Conbercept for patients with age-related macular degeneration: a systematic review. BMC Ophthalmol. 2018;18(1), 142.
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(3), 426–36.
   PubMed Web of Science ®Google Scholar
• Guo MY, Cheng J, Etminan M, Zafari Z. Maberley D One year effectiveness study of intravitreal aflibercept in neovascular age-related macular degeneration: a meta-analysis. Acta Ophthalmol. 2019;97(1), e1–e7.
   PubMed Web of Science ®Google Scholar
• Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther. 2015;9, 2311–20.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhou P, Li X, Wang H, Luo D, Qiao H, Ke X, Huang J. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling. PLoS One. 2013;8(3), e57642.
   PubMed Web of Science ®Google Scholar
• Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H. The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res. 2009;26(1), 204–10.
   PubMed Web of Science ®Google Scholar
• Peng Y, Zhang X, Mi L, Liu B, Zuo C, Li M, Wen F. Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy. BMC Ophthalmol 2017;17(1), 87.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, Yu DC. KH902 Phase 1 Study Group. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology.2011;118(4), 672–78.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys. Mol Vis. 2008;14, 37–49.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Han Q, Ru Y, Bo Q, Wei RH. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. Drug Des Devel Ther. 2015;9, 3413–21.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Guymer R. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration. Expert Rev Clin Pharmacol. 2015;8(5), 541–48.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423), 841–44.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3), 353–64.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801), 249–57.
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45(8), 2666–73.
   PubMed Web of Science ®Google Scholar
• Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18(6), 502–08.
   PubMed Web of Science ®Google Scholar
• Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15(1), 102–11.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4), 273–86.
   PubMed Web of Science ®Google Scholar
• Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat. 2002;200(6), 581–97.
   PubMed Web of Science ®Google Scholar
• Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J. 1996;15(2), 290–98.
   PubMed Web of Science ®Google Scholar
• Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem. 1996;271(10), 5638–46.
   PubMed Web of Science ®Google Scholar
• Yu DC, Lee JS, Yoo JY, Shin H, Deng H, Wei Y, Yun CO. Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol Ther. 2012;20(5), 938–47.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et al.. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17), 11393–98.
   PubMed Web of Science ®Google Scholar
• Qu J, Cheng Y, Li X, Yu L, Ke X; AURORA Study Group. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the AURORA study. Retina. 2016;36(5), 926–37.
   PubMed Web of Science ®Google Scholar
• Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, et al.. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014;121(9), 1740–47.
   PubMed Web of Science ®Google Scholar
• Congdon N, O’Colmain B, Klaver CC, Klein R, Muñoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;477–85.
   PubMedGoogle Scholar
• Green WR, Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology1993;100(10), 1519–35.
   PubMed Web of Science ®Google Scholar
• Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24), 2606–17.
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;1929–34.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27), 2805–16.
   PubMed Web of Science ®Google Scholar
• Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP; Macugen AMD Study Group. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology. 2007;114(9), 1702–12.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Monés J, Richard G, Bandello F, et al.. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9), 1144–67.
   PubMed Web of Science ®Google Scholar
• American academy of ophthalmology. Age-related macular degeneration PPP 2019. Available at: https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp.
   Google Scholar
• Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3, CD005139
   PubMed Web of Science ®Google Scholar
• Khanna S, Komati R, Eichenbaum DA, Hariprasad I, Ciulla TA, Hariprasad SM. Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol. 2019;4(1), e000398.
   PubMed Web of Science ®Google Scholar
• Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, Dong X, Zhang M, Xing Y, Zhu S, et al.. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol. 2019;197(1), 156–67.
   PubMed Web of Science ®Google Scholar
• Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, et al.. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12), 2537–48.
   PubMed Web of Science ®Google Scholar
• Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. 2016. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age-related macular degeneration. The BRAMD study. PLoS One, 11(5), e0153052. doi:10.1371/journal.pone.0153052
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14), 1432–44.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, JaJe GJ; CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20), 1897–908.
   PubMed Web of Science ®Google Scholar
• Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S, et al.. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3), 266–71.
   PubMed Web of Science ®Google Scholar
• Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120(11), 2300–09.
   PubMed Web of Science ®Google Scholar
• Cui J, Sun D, Lu H, Dai R, Xing L, Dong H, Wang L, Wei D, Jiang B, Jiao Y, et al.. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye 2018;32(2), 391–99.
   PubMed Web of Science ®Google Scholar
• Gao Y, Yu T, Zhang Y, Dang G. Anti-VEGF monotherapy versus photodynamic therapy and anti-VEGF combination treatment for neovascular age-related macular degeneration: A meta-analysis. Invest Ophthalmol Vis Sci. 2018;59(10), 4307–17.
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E, et al.. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012;32(8), 1453–64.
   PubMed Web of Science ®Google Scholar
• Ho CPS, Lai TYY. Current management strategy of polypoidal choroidal vasculopathy. Indian J Ophthalmol. 2018;66(12), 1727–35.
   PubMed Web of Science ®Google Scholar
• Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, et al.. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121(10), 1392–96.
   PubMedGoogle Scholar
• Otani A, Takagi H, Oh H, Koyama S, Ogura Y, Matumura M, Honda Y.. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002;64(1), 162–69.
   PubMed Web of Science ®Google Scholar
• Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, Wong TY, Aung T. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1), 19–29.
   PubMed Web of Science ®Google Scholar
• Wong C, Yanagi Y, Lee W, Ogura Y, Yeo I, Wong T, Cheung CMG. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53(4), 107–39.
   PubMed Web of Science ®Google Scholar
• Teo K, Gillies M, Fraser-Bell S. The use of vascular endothelial growth factor inhibitors and complementary treatment options in polypoidal choroidal vasculopathy: A subtype of neovascular age-related macular degeneration. Int J of Mol Sci. 2018;19(9), 2611.
   PubMed Web of Science ®Google Scholar
• Lam WC, Choudhry N, Wong D. Polypoidal choroidal vasculopathy in Canada. Can J Ophthalmol. 2019;Dec 23, pii: S0008-4182(19)30555–1.
   Web of Science ®Google Scholar
• Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br J Ophthalmol. 2010;94(3), 297–301.
   PubMed Web of Science ®Google Scholar
• Miyamoto N, Mandai M, Oishi A, Nakai S, Honda S, Hirashima T, Oh H, Matsumoto Y, Uenishi M, Kurimoto Y. Long-term results of photodynamic therapy or ranibizumab for polypoidal choroidal vasculopathy in LAPTOP study. Br J Ophthalmol. 2019;103(6), 844–48.
   PubMed Web of Science ®Google Scholar
• Lee JE, Shin JP, Kim HW, Chang W, Kim YC, Lee SJ, Chung IY, Lee JE. VAULT study group. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study. Graefes Arch Clin Exp Ophthalmol. 2017;255(3), 493–502.
   PubMed Web of Science ®Google Scholar
• Chen SN, Cheng CK, Yeung L, Chen JT, Chan WC, Liu JH, Sheu SJ, Wu WC, Lai CC. One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study. Int J Ophthalmol. 2018;11(11), 1802–08.
   PubMed Web of Science ®Google Scholar
• Qi HJ, Jin EZ, Zhao MW. One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data. Int J Ophthalmol. 2019;12(1), 51–57.
   PubMed Web of Science ®Google Scholar
• Peng Y, Zhang X, Li M, Liu B, Mi L, Zuo C, Wen F. Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy. Drug Des Devel Ther. 2018;12, 339–45.
   PubMed Web of Science ®Google Scholar
• Huang Z, Ding Q, Yan M, Lian H, Chen Z, Chen X, Song Y. Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy. Retina. 2019;39(5), 889–95.
   PubMed Web of Science ®Google Scholar
• Kokame GT, Liu K, Kokame KA, Kaneko KN, Omizo JN. Clinical characteristics of polypoidal choroidal vasculopathy and anti-vascular endothelial growth factor treatment response in Caucasians. Ophthalmologica. 2019;8, 1–9.
   Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13), 1227–39.
   PubMed Web of Science ®Google Scholar
• Sohn EH, van Dijk HW, Jiao C, Kok PH, Jeong W, Demirkaya N, Garmager A, Wit F, Kucukevcilioglu M, van Velthoven ME, et al.. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci USA 2016113(19), E2655–2664.
   PubMed Web of Science ®Google Scholar
• Lechner J, O’Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017.139(10), 7–14.
   PubMed Web of Science ®Google Scholar
• Pham B, Thomas SM, Lillie E, Lee T, Hamid J, Richter T, Janoudi G, Agarwal A, Sharpe JP, Scott A, et al.. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open 2019;9(5), e022031.
   PubMed Web of Science ®Google Scholar
• Pakzad-Vaezi K, Albiani DA, Kirker AW, Merkur AB, Kertes PJ, Eng KT, Fallah N, Forooghian F. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2014;45(6), 521–24.
   PubMed Web of Science ®Google Scholar
• Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: A systematic review and meta-analysis. Retina. 2015;35(10), 1931–42.
   PubMed Web of Science ®Google Scholar
• Lu Q, Lu L, Chen B, Chen W, Lu P. Efficacy comparison of intravitreal injections of conbercept and ranibizumab for severe proliferative diabetic retinopathy. Can J Ophthalmol. 2019;54(3), 291–96.
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23(1), 108–11.
   PubMed Web of Science ®Google Scholar
• Yang KB, Zhang H, Li SJ, Cao JJ, Cheng LN, Lin YX, Tian ZC, Li J, Gu F, Liu ZL. Conbercept and ranibizumab pretreatments in vitrectomy with silicone oil infusion for severe diabetic retinopathy. J Ocul Pharmacol Ther. 2019;35(3), 161–67.
   PubMed Web of Science ®Google Scholar
• Cui J, Chen H, Lu H, Dong F, Wei D, Jiao Y, Charles S, Gu W, Wang L. Efficacy and safety of intravitreal conbercept, ranibizumab, and triamcinolone on 23-gauge vitrectomy for patients with proliferative diabetic retinopathy. J Ophthalmol. 2018;2018, 4927259.
   PubMed Web of Science ®Google Scholar
• Ren X, Bu S, Zhang X, Jiang Y, Tan L, Zhang H, Li X. Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy. Eye. 2019;33(7), 1177–83.
   PubMed Web of Science ®Google Scholar
• Li F, Zhang L, Wang Y, Xu W, Jiao W, Ma A, Zhao B. One-year outcome of conbercept therapy for diabetic macular edema. Curr Eye Res. 2018;43(2), 218–23.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wu C, Zhou LJ, Dai RP. Observation of optic disc neovascularization using OCT angiography in proliferative diabetic retinopathy after intravitreal Conbercept injections. Sci Rep. 2018;8(1), 3972.
   PubMed Web of Science ®Google Scholar
• He F, Yu W. Longitudinal neovascular changes on optical coherence tomography angiography in proliferative diabetic retinopathy treated with panretinal photocoagulation alone versus with intravitreal conbercept plus panretinal photocoagulation: a pilot study. Eye. 2019 Nov 12. doi: 10.1038/s41433-019-0628-3
   Web of Science ®Google Scholar
• Grossniklaus HE, Green WR. Pathological findings in pathologic myopia. Retina. 199212(2), 127–33.
   PubMed Web of Science ®Google Scholar
• Lai TY, Cheung CM. Myopic choroidal neovascularization: diagnosis and treatment. Retina. 2016;36(9), 1614–21.
   PubMed Web of Science ®Google Scholar
• Wang E, Chen Y. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina. 201333(7), 1375–92.
   PubMed Web of Science ®Google Scholar
• Uemura A, Thomas MA. Subretinal surgery for choroidal neovascularization in patients with high myopia. Arch Ophthalmol. 2000;118(3), 344–50.
   PubMedGoogle Scholar
• Willis J, Morse L, Vitale S, Parke DW, Rich WL, Lum F, Cantrell RA. Treatment patterns for myopic choroidal neovascularization in the United States: analysis of the IRIS registry. Ophthalmology. 2017124(7), 935–43.
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin, 1-year results of a randomized clinical trial—VIP report No. 1. Ophthalmology. 2001;108(5), 841–52.
   PubMed Web of Science ®Google Scholar
• Teo KYC, Wei YN, Shu YL, Cheung CM. Management of myopic choroidal neovascularization: focus on anti-VEGF therapy. Drugs. 2016;76(11), 1119–33.
   PubMed Web of Science ®Google Scholar
• Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, et al.. Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology. 2017;124(11), 1690–711.
   PubMed Web of Science ®Google Scholar
• Cohen SY. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina. 2009;29(8), 1062–66.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yang S, Yuan Y, Song M, Kuang F, Liu K, Zhang F, Wang F, Sun X. Progression and new onset of macular retinoschisis in myopic choroidal neovascularization eyes after conbercept therapy: a post-hoc analysis. Eye. 2019 Jul 29. doi: 10.1038/s41433-019-0516-x
   Web of Science ®Google Scholar
• Shi XH, Wei WB. Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia. Zhonghua Yan Ke Za Zhi. 2019;55(10), 791–95.
   PubMedGoogle Scholar
• Wei Q, Jiang C, Ye X, Huang X, Jin H, Xu G. Vitreous proteomics provides new insights into antivascular endothelial growth factor therapy for pathologic myopia choroid neovascularization. J Interferon Cytokine Res. 2019;39(12), 786–96.
   PubMed Web of Science ®Google Scholar
• Yan M, Huang Z, Lian HY, Song YP, Chen X. Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol. 2019;97(5), e813–e814.
   PubMed Web of Science ®Google Scholar
• Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33(5), 901–10.
   PubMed Web of Science ®Google Scholar
• Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006244(3), 309–15.
   PubMed Web of Science ®Google Scholar
• Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. J Ophthalmol. 2017;2017, 4936924.
   PubMed Web of Science ®Google Scholar
• Li F, Sun M, Guo J, Ma A, Zhao B.. Comparison of conbercept with ranibizumab for the treatment of macular edema secondary to branch retinal vein occlusion. Curr Eye Res 2017;42(8), 1174–78.
   PubMed Web of Science ®Google Scholar
• Deng Y, Cai X, Zhang S, Su L, Chen H, Lin Y, Sun L, Chen G, Zhong L, Jin C, et al.. Quantitative analysis of retinal microvascular changes after conbercept therapy in branch retinal vein occlusion using optical coherence tomography angiography. Ophthalmologica. 2019;242(2), 69–80.
   PubMed Web of Science ®Google Scholar
• Tao Y, Huang C, Liu M, Sun L, Li L, Wei Y, Yu X, Wang H. Short-term effect of intravitreal conbercept injection on major and macular branch retinal vein occlusion. J Int Med Res. 2019;47(3), 1202–09.
   PubMed Web of Science ®Google Scholar
• Xia JP, Wang S, Zhang JS.. The anti-inflammatory and anti-oxidative effects of conbercept in treatment of macular edema secondary to retinal vein occlusion. Biochem Biophys Res Commun 2019;508(4), 1264–70.
   PubMed Web of Science ®Google Scholar
• Ferrari G, Dastjerdi MH, Okanobo A, Cheng SF, Amparo F, Nallasamy N, Dana R. Topical ranibizumab as a treatment of corneal neovascularization. Cornea. 2013;32(7), 992–97.
   PubMed Web of Science ®Google Scholar
• Lee P, Wang CC, Adamis AP.. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43(30), 245–69.
   PubMed Web of Science ®Google Scholar
• Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, Laibson PR, Cohen EJ. Corneal neovascularization after penetrating keratoplasty. Cornea. 1995:604–09.
   PubMed Web of Science ®Google Scholar
• Zhai LY, Zhang XR, Liu H, Ma Y, Xu HC. Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study. Eye. 2019 Nov 29 . doi: 10.1038/s41433-019-0717-3
   Web of Science ®Google Scholar
• Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 201257(5), 415–29.
   PubMed Web of Science ®Google Scholar
• Gupta D, Illingworth C. Treatments for corneal neovascularization: a review. Cornea. 2011;30(8), 927–38.
   PubMed Web of Science ®Google Scholar
• Bock F, Ko¨nig Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2008;246(2), 281–84.
   PubMed Web of Science ®Google Scholar
• Zhou AY, Bai YJ, Zhao M, Yu WZ, Li XX. KH902, a recombinant human VEGF receptor fusion protein, reduced the level of placental growth factor in alkali burn induced-corneal neovascularization. Ophthalmic Res, 50(3), 180–86. doi:10.1159/000353437
   PubMed Web of Science ®Google Scholar
• Wu Y, Xue C, Lu Y, Huang Z. The inhibitory effect of different concentrations of KH902 eye drops on corneal neovascularization induced by alkali burn. Indian J Ophthalmol. 2017;65(11), 1127–32.
   PubMed Web of Science ®Google Scholar
• Ayyala RS, Zurakowski D, Monshizadeh R, Hong CH, Richards D, Layden WE, Hutchinson BT, Bellows AR. Comparison of double-plate Molteno and Ahmed glaucoma valve in patients with advanced uncontrolled glaucoma. Ophthalmic Surg Lasers. 2002:94–101.
   PubMedGoogle Scholar
• Shchomak Z, Cordeiro Sousa D, Leal I, Abegão Pinto L. Surgical treatment of neovascular glaucoma: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol. 2019;257(6), 1079–89.
   PubMed Web of Science ®Google Scholar
• Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2016;55, 196–204.
   PubMedGoogle Scholar
• Christakis PG, Tsai JC, Kalenak JW, Zurakowski D, Cantor LB, Kammer JA, Ahmed II. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology. 2013;120(11), 2232–40.
   PubMed Web of Science ®Google Scholar
• Marra KV, Wagley S, Omar A, Kinoshita T, Kovacs KD, Silva P, Kuperwaser MC, Arroyo JG. Case-matched comparison of vitrectomy, peripheral retinal endolaser, and endocyclophotocoagulation versus standard care in neovascular glaucoma. Retina. 2015;35(6), 1072–83.
   PubMed Web of Science ®Google Scholar
• Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108(10), 1767–76.
   PubMed Web of Science ®Google Scholar
• Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma. 2010;19(9), 622–26.
   PubMed Web of Science ®Google Scholar
• Shi L, Yang J, Lin J. What is the impact of intravitreal injection of conbercept on neovascular glaucoma patients: a prospective, interventional case series study. BMC Ophthalmol. 2019;19(1), 128.
   PubMed Web of Science ®Google Scholar
• Zhang L, Ke Y, Wang W, Shi X, Hei K, Li X. The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease. Graefes Arch Clin Exp Ophthalmol. 2018;256(7), 1339–46.
   PubMed Web of Science ®Google Scholar
• Wu P, Shi D, Chen X, Feng C, Xu H, Lin P. Long-term efficacy of intravitreal conbercept injection in the treatment of idiopathic choroidal neovascularization. J Ocul Pharmacol Ther. 2019 Nov 21. doi: 10.1089/jop.2019.0075
   PubMed Web of Science ®Google Scholar
• Zhang J, Tian Q, Zheng T, Chen D, Wang Q, Ke M. Effect of multiple subconjunctival conbercept injections as an adjuvant to the surgical treatment of pterygium: a prospective randomised comparative 6-month follow-up study. Eye. 2020;34(2), 408–14.
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27(7), 787–94.
   PubMed Web of Science ®Google Scholar
• van der Reis MI, La Heij EC, De Jong-Hesse Y, Ringens PJ, Hendrikse F, Schouten JS. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011;31(8), 1449–69.
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol. 2011;56(2), 95–113.
   PubMed Web of Science ®Google Scholar
• Jeon S, Lee WK. Intravitreal bevacizumab increases intraocular interleukin-6 levels at 1 day after injection in patients with proliferative diabetic retinopathy. Cytokine. 2012;60(2), 535–39.
   PubMed Web of Science ®Google Scholar
• Forooghian F, Kertes PJ, Eng KT, Agron E, Chew EY. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci. 2010;51(5), 2388–92.
   PubMed Web of Science ®Google Scholar
• Romano MR, Biagioni F, Besozzi G, Carrizzo A, Vecchione C, Fornai F, Lograno MD. Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res. 2012;1478, 55–63.
   PubMed Web of Science ®Google Scholar
• Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J, Spitzer MS, Bartz-Schmidt KU, Szurman P, Lüke M, Aisenbrey S. 2014. Electrophysiological toxicity testing of VEGF trap-eye in an isolated perfused vertebrate retina organ culture model. Acta Ophthalmol (Copenh). 201492(4), e305–311.
   Web of Science ®Google Scholar
• Xu W, Cheng W, Yao Y, Guo J, Xu G. Preoperative intravitreal conbercept facilitates vitrectomy in proliferative diabetic retinopathy: is attention required for the fellow eye? J Ophthalmol. 20192019, 2923950.
   PubMed Web of Science ®Google Scholar
• Sun CB, Wang Y, Zhou S, Fang X, Xu D, Liu Z. Macular hole retinal detachment after intravitreal Conbercept injection for the treatment of choroidal neovascularization secondary to degenerative myopia: a case report. BMC Ophthalmol. 2019;19(1), 156.
   PubMed Web of Science ®Google Scholar
• Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye. 2011;25(6), 710–16.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, et al.. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 2014;121(1), 193–201.
   PubMed Web of Science ®Google Scholar